Maximus (MMS) Projected to Post Earnings on Thursday

Maximus (NYSE:MMS) will likely be posting its Q1 2026 results before the market opens on Thursday, February 5th. Analysts expect Maximus to post earnings of $1.84 per share and revenue of $1.3749 billion for the quarter. Maximus has set its FY 2026 guidance at 7.950-8.250 EPS. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, February 5, 2026 at 9:00 AM ET.

Maximus (NYSE:MMS) last released its quarterly earnings data on Thursday, November 20th. The health services provider reported $1.62 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.01). Maximus had a net margin of 5.87% and a return on equity of 25.23%. The company had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.34 billion. During the same period last year, the company earned $1.46 EPS. The firm’s revenue for the quarter was up .2% on a year-over-year basis. On average, analysts expect Maximus to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Maximus Trading Down 2.0%

Shares of MMS stock opened at $94.90 on Thursday. The company has a current ratio of 1.64, a quick ratio of 1.64 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $5.18 billion, a price-to-earnings ratio of 17.07 and a beta of 0.56. Maximus has a 12-month low of $63.77 and a 12-month high of $100.00. The stock’s 50-day moving average price is $89.63 and its 200-day moving average price is $85.62.

Maximus Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 2nd. Shareholders of record on Friday, February 13th will be issued a dividend of $0.33 per share. The ex-dividend date is Friday, February 13th. This represents a $1.32 annualized dividend and a yield of 1.4%. This is a boost from Maximus’s previous quarterly dividend of $0.30. Maximus’s dividend payout ratio (DPR) is 21.58%.

Wall Street Analyst Weigh In

MMS has been the topic of several recent research reports. Zacks Research raised Maximus from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 30th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Maximus in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Strong Buy”.

Insider Activity at Maximus

In other news, insider Michelle F. Link sold 4,039 shares of the business’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $86.84, for a total transaction of $350,746.76. Following the transaction, the insider owned 19,542 shares of the company’s stock, valued at approximately $1,697,027.28. The trade was a 17.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 1.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Advisory Services Network LLC purchased a new stake in shares of Maximus in the third quarter valued at $32,000. Canada Pension Plan Investment Board bought a new position in Maximus during the 2nd quarter valued at about $35,000. Danske Bank A S bought a new position in Maximus during the 3rd quarter valued at about $55,000. National Bank of Canada FI raised its position in Maximus by 38.9% in the 3rd quarter. National Bank of Canada FI now owns 1,118 shares of the health services provider’s stock worth $102,000 after purchasing an additional 313 shares during the period. Finally, Wexford Capital LP bought a new stake in Maximus in the third quarter worth about $114,000. 97.21% of the stock is owned by hedge funds and other institutional investors.

Maximus Company Profile

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.